Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Journal of hepatology
- Publicado em
- 31 mai 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis
Candid Villanueva, Ferran Torres, Shiv Kumar Sarin, Hasnain Ali Shah, Dhiraj Tripathi, Anna Brujats, Susana G Rodrigues, Ankit Bhardwaj, Zahid Azam, Peter C Hayes et al.
Descritores MeSH
- Hypertension, Portal
- Esophageal and Gastric Varices
- Ascites
- Humans
- Liver Cirrhosis
- Randomized Controlled Trials as Topic
- Carvedilol
- Portal Pressure
- Adrenergic beta-Antagonists
Veja também
Estudos relacionados
- Comparison of Carvedilol and Propranolol in Reducing the Portal Vein Pressure: A Systematic Review and Meta-analysis
- Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta-Analysis
- Carvedilol and traditional nonselective beta blockers for the secondary prophylaxis of variceal hemorrhage and portal hypertension related complications among patients with decompensated cirrhosis: a systematic review and network meta-analysis
- Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial)